Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study

Kazuhide Kawase, Jason L Vittitow, Robert N Weinreb, Makoto Araie, JUPITER Study Group, Shigeru Hoshiai, Setsuko Hashida, Miki Iwasaki, Kiyoshi Kano, Kazuhide Kawase, Takuji Kato, Yasuaki Kuwayama, Tomoyuki Muramatsu, Masatada Mitsuhashi, Sakae Matsuzaki, Toru Nakajima, Isao Sato, Yuzuru Yoshimura, Kazuhide Kawase, Jason L Vittitow, Robert N Weinreb, Makoto Araie, JUPITER Study Group, Shigeru Hoshiai, Setsuko Hashida, Miki Iwasaki, Kiyoshi Kano, Kazuhide Kawase, Takuji Kato, Yasuaki Kuwayama, Tomoyuki Muramatsu, Masatada Mitsuhashi, Sakae Matsuzaki, Toru Nakajima, Isao Sato, Yuzuru Yoshimura

Abstract

Introduction: Latanoprostene bunod (LBN) is a novel nitric oxide (NO)-donating prostaglandin F2α analog. We evaluated the long-term safety and intraocular pressure (IOP)-lowering efficacy of LBN ophthalmic solution 0.024% over 1 year in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Methods: This was a single-arm, multicenter, open-label, clinical study. Subjects aged 20 years and older with a diagnosis of OAG or OHT instilled 1 drop of LBN ophthalmic solution 0.024% in the affected eye(s) once daily in the evening for 52 weeks and were evaluated every 4 weeks. Safety assessments included vital signs, comprehensive ophthalmic exams, and treatment-emergent adverse events (AEs). Absolute and percent reductions from baseline in IOP were also determined.

Results: Of 130 subjects enrolled, 121 (93.1%) completed the study. Mean age was 62.5 years, and mean (standard deviation) baseline IOP was 19.6 (2.9) and 18.7 (2.6) mmHg in study eyes and treated fellow eyes, respectively. Overall, 76/130 (58.5%) and 78/126 (61.9%) subjects experienced ≥1 AEs in study eyes and treated fellow eyes, respectively. In both study eyes and treated fellow eyes, the most common AEs were conjunctival hyperemia, growth of eyelashes, eye irritation, and eye pain. At 52 weeks, 9% of treated eyes had an increase in iris pigmentation compared with baseline based on iris photographs. No safety concerns emerged based on vital signs or other ocular assessments. Mean reductions from baseline in IOP of 22.0% and 19.5% were achieved by week 4 in study and treated fellow eyes, respectively. These reductions were maintained through week 52 (P < 0.001 vs. baseline at all visits).

Conclusion: Once daily LBN ophthalmic solution 0.024% was safe and well-tolerated in Japanese subjects with OAG or OHT when used for up to 1 year. Long-term treatment with LBN ophthalmic solution 0.024% provided significant and sustained IOP reduction.

Trial registration: ClinicalTrials.gov identifier, NCT01895972.

Funding: Bausch & Lomb, Inc. a division of Valeant Pharmaceuticals International Inc.

Keywords: Intraocular pressure; Nitric oxide; Ocular hypertension; Open-angle glaucoma; Ophthalmology; Prostaglandin.

Figures

Fig. 1
Fig. 1
Metabolism of latanoprostene bunod to latanoprost acid (1) and butanediol mononitrate with subsequent release of nitric oxide (2) and 1,4-butanediol, an inactive metabolite
Fig. 2
Fig. 2
Mean IOP (mmHg) at each study visit in the study eye and the treated fellow eye (safety population). All post-baseline measurements P < 0.001 vs. baseline. Standard deviations at each timepoint ranged from 2.31 to 3.00 mmHg. IOP intraocular pressure
Fig. 3
Fig. 3
Reduction from baseline in mean IOP (mmHg) by visit (safety population). All data points P < 0.001 for reduction from baseline. Standard deviations at each timepoint ranged from 2.61 to 2.88 mmHg. IOP intraocular pressure

References

    1. Broman AT, Quigley HA, West SK, et al. Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. Invest Ophthalmol Vis Sci. 2008;49(1):66–76. doi: 10.1167/iovs.07-0866.
    1. Heijl A, Bengtsson B, Hyman L, Leske MC. Early manifest glaucoma trial group. Natural history of open-angle glaucoma. Ophthalmology. 2009;116(12):2271–2276. doi: 10.1016/j.ophtha.2009.06.042.
    1. Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152(4):515–522. doi: 10.1016/j.ajo.2011.06.004.
    1. Medeiros FA, Gracitelli CP, Boer ER, Weinreb RN, Zangwill LM, Rosen PN. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology. 2015;122(2):293–301. doi: 10.1016/j.ophtha.2014.08.014.
    1. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268–1279. doi: 10.1001/archopht.120.10.1268.
    1. Investigators AGIS. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440. doi: 10.1016/S0002-9394(00)00538-9.
    1. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–1953. doi: 10.1016/S0161-6420(01)00873-9.
    1. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56. doi: 10.1001/archopht.121.1.48.
    1. Collaborative Normal-Tension Glaucoma Study Group Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–497. doi: 10.1016/S0002-9394(98)00223-2.
    1. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomized, multicenter, placebo-controlled trial. Lancet. 2015;385:1295–1304. doi: 10.1016/S0140-6736(14)62111-5.
    1. American Academy of Ophthalmology. Preferred Practice Pattern. Primary open-angle glaucoma. 2015. . Accessed 22 Feb 2016.
    1. The Japan Glaucoma Society Guidelines for Glaucoma (3rd Edition). Nippon Ganka Gakkai zasshi 2012;116(1):3–46.
    1. Medeiros FA, Susanna R, Singh K. Who should be treated. In: Weinreb RN, Araie M, Susanna R, Goldberg I, Migdal C, Liebmann J, editors. Medical treatment of glaucoma: WGA consensus series 7. Kugler, Amsterdam:The Netherlands; 2010.
    1. Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015;31:63–77. doi: 10.1089/jop.2014.0067.
    1. Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin. 2007;23(3):601–608. doi: 10.1185/030079907X178720.
    1. Camras CB, Schumer RA, Marsk A, et al. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol. 1992;110(12):1733–1738. doi: 10.1001/archopht.1992.01080240073034.
    1. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103(1):138–147. doi: 10.1016/S0161-6420(96)30749-5.
    1. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122(7):957–965. doi: 10.1001/archopht.122.7.957.
    1. Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014;8:1967–1985.
    1. Schmier JK, Hulme-Lowe CK, Covert DW. Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. Clin Ophthalmol. 2014;10(8):1097–1104. doi: 10.2147/OPTH.S63760.
    1. Krauss AH, Impagnatiello F, Toris CB, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp Eye Res. 2011;93(3):250–255. doi: 10.1016/j.exer.2011.03.001.
    1. Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738–745. doi: 10.1136/bjophthalmol-2014-305908.
    1. Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2a. Exp Eye Res. 1988;47:761–769. doi: 10.1016/0014-4835(88)90043-7.
    1. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389–402. doi: 10.1016/0014-4835(89)90049-3.
    1. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707–716. doi: 10.1016/0014-4835(89)90011-0.
    1. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100(9):1297–1304. doi: 10.1016/S0161-6420(93)31484-3.
    1. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38:2214–2223.
    1. Richter M, Krauss AH, Woodward DF, Lütjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44:4419–4426. doi: 10.1167/iovs.02-1281.
    1. Cavet ME, Vollmer TR, Harrington KL, VanDerMeid K, Richardson ME. Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. Invest Ophthalmol Vis Sci. 2015;56(6):4108–4116. doi: 10.1167/iovs.14-16015.
    1. Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci. 1994;35:2515–2520.
    1. Saeki T, Tsuruga H, Aihara M, Rittenhouse K. Dose-response profile of PF-03187207 (PF-207) and peak IOP lowering response following single topical administration to FP receptor knockout mice vs. wild type mice. Invest Ophthalmol Vis Sci. 2009;50:E-abstract 4064. . Accessed 22 Feb 2016.
    1. Araie M, Sforzolini BS, Vittitow J, Weinreb RN. Evaluation of the effect of latanoprostene bunod ophthalmic solution, 0.024% in lowering intraocular pressure over 24 h in healthy Japanese subjects. Adv Ther. 2015;32(11):1128–1139. doi: 10.1007/s12325-015-0260-y.
    1. Weinreb RN, Sforzolini BS, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% vs timolol maleate 0.5% in the treatment of open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965–973. doi: 10.1016/j.ophtha.2016.01.019.
    1. Liu JHK, Slight JR, Vittitow JL, et al. Efficacy of latanoprostene bunod 0.024% compared with timolol 0.5% in lowering intraocular pressure over 24 hours. Am J Ophthalmol. 2016 (Epub ahead of print).
    1. Medeiros FA, Martin KR, Peace J, et al. Comparison of Latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016
    1. Schuman JS. Short- and long-term safety of glaucoma drugs. Expert Opin Drug Saf. 2002;1:181–194. doi: 10.1517/14740338.1.2.181.
    1. Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003;19:23–35. doi: 10.1089/108076803762718088.
    1. Teus MA, Arranz-Marquez E, Lucea-Suescun P. Incidence of iris colour change in latanoprost treated eyes. Br J Opthalmol. 2002;86:1085–1088. doi: 10.1136/bjo.86.10.1085.
    1. Tressler CS, Wiseman RL, Dombi TM, et al. Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature. Br J Ophthalmol. 2011;95:1490–1495. doi: 10.1136/bjo.2010.193987.
    1. Chiba T, Kashiwagi K, Chiba N, et al. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study. Br J Ophthalmol. 2003;87(8):956–959. doi: 10.1136/bjo.87.8.956.
    1. Chiba T, Kashiwagi K, Ishijima K, et al. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol. 2004;48(2):141–147. doi: 10.1007/s10384-003-0039-6.
    1. Hara T. Increased iris pigmentation after use of latanoprost in Japanese brown eyes. Nippon Ganka Gakkai Zasshi. 2001;105(5):314–321.
    1. Latanoprost-Induced Iris Pigmentation Study Group Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes. Jpn J Ophthalmol. 2006;50(2):96–99. doi: 10.1007/s10384-005-0288-7.
    1. Suzuki M, Mishima HK, Masuda K, Araie M, Kitazawa Y, Azuma I. Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan. Jpn J Ophthalmol. 2000;44:33–38. doi: 10.1016/S0021-5155(99)00147-1.
    1. Obstbaum SA, Cioffi GA, Krieglstein GK, et al. Gold standard medical therapy for glaucoma: defining the criteria identifying measures for an evidence-based analysis. Clin Ther. 2004;26(12):2102–2120. doi: 10.1016/j.clintera.2004.12.007.
    1. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol. 2002;120:701–703. doi: 10.1001/archopht.120.6.701.
    1. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863–868. doi: 10.1016/j.ophtha.2004.12.026.
    1. Bayer A, Weiler W, Oeverhaus U, Skrotzki FE, Stewart WC, Xplore Observation Group Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther. 2004;20(6):470–478. doi: 10.1089/jop.2004.20.470.
    1. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002;47(Suppl 1):S65–S76. doi: 10.1016/S0039-6257(02)00301-6.
    1. Watson PG. Latanoprost. Two years’ experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105(1):82–87. doi: 10.1016/S0161-6420(98)91372-0.
    1. Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye (Lond). 2004;18(10):984–989. doi: 10.1038/sj.eye.6701373.
    1. Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535–540. doi: 10.1097/IJG.0000000000000073.
    1. Schmier JK, Lau EC, Covet DW. Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. Clin Ophthalmol. 2010;4:1137–1143. doi: 10.2147/OPTH.S13884.
    1. Sheleg T. Normal-tension (low-tension) glaucoma, glaucoma-basic and clinical concepts. Dr. Shimon Rumelt (ed). ISBN:978-953-307-591-4. InTech. . Accessed 20 Feb 2016.
    1. Anderson DR. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14(2):86–90. doi: 10.1097/00055735-200304000-00006.
    1. Koseki N, Araie M, Shirato S, Yamamoto S. Effect of trabeculectomy on visual field performance in central 30 degrees field in progressive normal-tension glaucoma. Ophthalmology. 1997;104(2):197–201. doi: 10.1016/S0161-6420(97)30334-0.
    1. Shigeeda T, Tomidokoro A, Araie M, Koseki N, Yamamoto S. Long-term follow-up of visual field progression after trabeculectomy in progressive normal-tension glaucoma. Ophthalmology. 2002;109(4):766–770. doi: 10.1016/S0161-6420(01)01009-0.
    1. Kim M, Kim DM, Park KH, Kim TW, Jeoung JW, Kim SH. Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma: a 12-year mean follow-up study. Acta Ophthalmol. 2013;91(4):e270–e275. doi: 10.1111/aos.12082.
    1. Liu CJ, Ko YC, Cheng CY, et al. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Ophthalmology. 2002;109(12):2241–2247. doi: 10.1016/S0161-6420(02)01247-2.
    1. McKibbin M, Menage MJ. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye (Lond). 1999;13(Pt 1):31–34. doi: 10.1038/eye.1999.6.
    1. Quaranta L, Pizzolante T, Riva I, Haidich AB, Konstas AG, Stewart WC. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol. 2008;92(9):1227–1231. doi: 10.1136/bjo.2008.138024.
    1. Tsumura T, Yoshikawa K, Suzumura H, et al. Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. Clin Ophthalmol. 2012;6:1547–1552. doi: 10.2147/OPTH.S36628.
    1. Vittitow JL, Liebmann JM, Kaufman PL, et al. Long-term efficacy and safety of latanoprostene bunod 0.024% for intraocular pressure lowering in patients with open-angle glaucoma or ocular hypertension: APOLLO and LUNAR studies. In: Presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting, Seattle, WA, May 1–5, 2016.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa